Cancer Research UK, Abcam partner on cancer antibodies

By The Science Advisory Board staff writers

Abcam will create protein-based reagents for targets identified by Cancer UK-funded researchers. Antibodies that result from the partnership will be used to further understand cancer biology, create new diagnostic tools, and potentially develop novel therapies.

Under the terms of the agreement, the Cancer UK-funded researchers can request Abcam to supply antibodies developed from the partnership for an agreed period of exclusivity. After the unspecified period of exclusivity ends, Abcam will utilize its supply capability to make the antibodies available to the wider research and diagnostic development community.

Copyright © 2020

To read this and get access to all of the exclusive content on The Science Advisory Board create a free account or sign-in now.

Member Sign In:
MemberID or email address:  
Do you have a password?
No, I want a free membership.
Yes, I have a password:  
Forgot your password?
Sign in using your social networking account:
Sign in using your social networking